Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress
Aurinia Pharmaceuticals Inc - Common Shares (AUPH)
Last aurinia pharmaceuticals inc - common shares earnings: 3/5 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.auriniapharma.com
Company Research
Source: Business Wire
Full Year 2025 LUPKYNIS Sales Grew 25%Announces LUPKYNIS Sales Guidance for 2026 of $305 Million to $315 Million ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and twelve months ended December 31, 2025 and provided an update on recent business progress.Financial ResultsTotal Revenue: For the three and twelve months ended December 31, 2025, total revenue was $77.1 million and $283.1 million, up 29% and 20%, respectively, compared to $59.9 million and $235.1 million, respectively, for the same periods of 2024.Net Product Sales: For the three and twelve months ended December 31, 2025, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were $74.2 million and $271.3 million, up 29% and 25%, respectively, compared to $57.6 million and $216.2 million, respectively, for the same periods of 2024.License, Collaborat
Show less
Read more
Impact Snapshot
Event Time:
AUPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AUPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AUPH alerts
High impacting Aurinia Pharmaceuticals Inc - Common Shares news events
Weekly update
A roundup of the hottest topics
AUPH
News
- Should Aurinia's Surging 2025 Earnings and Upbeat 2026 Outlook Require Action From Aurinia (AUPH) Investors? [Yahoo! Finance]Yahoo! Finance
- Aurinia Pharmaceuticals (AUPH) Reports Financial Results for Three and Twelve Months Ended December 31, 2025 [Yahoo! Finance]Yahoo! Finance
- Aurinia Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Aurinia: Q4 Earnings Snapshot [Yahoo! Finance]Yahoo! Finance
- Aurinia Pharma GAAP EPS of $1.53 beats by $1.31, revenue of $77.1M beats by $2.4M [Seeking Alpha]Seeking Alpha
AUPH
Earnings
- 2/26/26 - Beat
AUPH
Sec Filings
- 3/3/26 - Form 4
- 3/3/26 - Form SCHEDULE
- 3/3/26 - Form 4
- AUPH's page on the SEC website